Результаты поиска

Многогранные биомаркеры предлагают аналогичный профиль патологии CNS в релапсации и прогрессивном MS.

СПРАВОЧНАЯ ИНФОРМАЦИЯ: Повторные выбросы (RR) и первичный прогрессивный (PP) множественный склероз (MS) имеют отдельные клинические курсы, однако основные патофизиологические различия остаются неясными. Мы сравнили патологические компоненты между RRMS, PPMS и другими воспалительными и нейродегенеративными расстройствами, используя растворимые биомаркеры и патологию после смерти. МЕТОДЫ: Серум и цереброспинская жидкость (CSF) у людей, у которых диагностированы (pw) РРМС (n = 104), RRMS (n = 38), болезнь Альцгеймера (AD, n = 22), спектральное расстройство нейромиелита (NMOSD, n = 10) и болезнь,

Совпадение в аннотации оригинала
BACKGROUND: Relapsing-remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory and neurodegenerative disorders, leveraging soluble biomarkers and post-mortem pathology. METHOD…

Paraneoplastic cerebellar degeneration mimicking development of secondary progressive multiple sclerosis in a patient with relapsing-remitting multiple sclerosis.

Paraneoplastic cerebellar degeneration (PCD) is a rare non-metastatic complication of cancer mediated by T lymphocytes and auto-antibodies directed against Purkinje cells of the cerebellum. We report a patient with relapsing-remitting multiple sclerosis who developed a progressive cerebellar syndrome with dysarthria, ataxic gait and vertigo mimicking development of secondary progressive multiple sclerosis but caused by anti-Yo antibody positive PCD associated with ovarian cancer, presenting an unusual diagnostic challenge.

Therapy with glatiramer acetate for multiple sclerosis.

BACKGROUND: Some clinical data have shown that glatiramer acetate (Copaxone), a synthetic amino acid polymer empirically found to suppress experimental allergic encephalomyelitis (EAE), an animal model of MS, might help improve the outcome of patients with multiple sclerosis (MS). OBJECTIVES: We performed a Cochrane review of all randomised, placebo-controlled trials of glatiramer acetate in MS, whatever the disease course. SEARCH STRATEGY: We searched the Cochrane MS Group trials register (June 2003), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2003), MEDLINE (Pub…

Помимо рецидивов: как ингибиторы BTK определяют будущее прогрессивного лечения MS.

Множественный склероз является биологически и клинически гетерогенным воспламенительным демиелинизирующим заболеванием, движущимся реанимирующими и прогрессивными механизмами, причем все люди испытывают разную степень и то, и другое. Существующая высокоэффективная терапия направлена на периферийные воспаления и снижает частоту рецидивов, но имеет ограниченную эффективность в прогрессивных MS из-за слабого проникновения мозгового барьера в кровь и неспособности справиться с нейродегенерацией. Тирозиновые киназы Брютона (BTK) представляют собой новый терапевтический класс, предлагающий новый мех

Совпадение в аннотации оригинала
Multiple sclerosis is a biologically and clinically heterogenous inflammatory demyelinating disease, driven by relapsing and progressive mechanisms, all individuals experiencing varying degrees of both. Existing highly effective therapies target peripheral inflammation and reduce relapse rates but have limited efficacy in progressive MS due to poor blood-bra…

Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis.

Multiple sclerosis (MS) is an idiopathic demyelinating disease in which meningeal inflammation correlates with accelerated disease progression. The study of meningeal inflammation in MS has been limited because of constrained access to MS brain/spinal cord specimens and the lack of experimental models recapitulating progressive MS. Unlike induced models, a spontaneously occurring model would offer a unique opportunity to understand MS immunopathogenesis and provide a compelling framework for translational research. We propose granulomatous meningoencephalomyelitis (GME) as a natural model to s…

Primary progressive multiple sclerosis and neurofibromatosis type 1.

BACKGROUND: Multiple sclerosis (MS) is a common inflammatory demyelinating disease of the central nervous system. The clinical phenotype is probably modified by interactions from genetic and environmental factors. Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disease. NF1 gene mutations lead to clinical manifestation in the peripheral and central nervous system. Coexistence of MS and NF1 is a rare condition. OBJECTIVE: To report the case of the patient with primary progressive MS (PPMS) and NF1. METHODS: A retrospective analysis of a patient who has undergone whole e…

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

BACKGROUND: Mesenchymal stem cells (MSCs) exhibit immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animals. Clinical trials in several human conditions support the safety and efficacy of MSC transplantation. Published experience in multiple sclerosis (MS) is modest. OBJECTIVE: To assess feasibility, safety, and tolerability and explore efficacy of autologous MSC transplantation in MS. METHODS: Participants with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS), Expanded Disability Status Scale score 3.0-6.5, d…

Cortical atrophy is relevant in multiple sclerosis at clinical onset.

INTRODUCTION: Increasing evidence suggests relevant cortical gray matter pathology in patients with Multiple Sclerosis (MS), but how early this pathology begins; its impact on clinical disability and which cortical areas are primarily affected needs to be further elucidated. METHODS: 115 consecutive patients (10 Clinically Isolated Syndrome (CIS), 32 possible MS (p-MS), 42 Relapsing Remitting MS (RR-MS), 31 Secondary Progressive MS (SP-MS)), and 40 age/gender-matched healthy volunteers (HV) underwent a neurological examination and a 1.5 T MRI. Global and regional Cortical Thickness (CTh) meas…

Tear CHI3L1 in multiple sclerosis: a non-invasive biomarker linked to disease progression.

OBJECTIVE: To evaluate tear CHI3L1 (tCHI3L1) as a minimally invasive biomarker in multiple sclerosis (MS), compare it with serum and cerebrospinal fluid (CSF) CHI3L1, and assess associations with clinical phenotype and disease measures. METHODS: This cross-sectional study included 111 MS patients (71 relapsing-remitting MS [RRMS] and 40 progressive MS [PMS]) and 23 healthy controls (HC). tCHI3L1 was quantified by optimized ELISA and normalized to tear volume (tCHI3L1 ratio). Paired tear-serum samples were available for 99 patients to measure sCHI3L1, sGFAP, and sNFL. Associations with age, Ex…

Cortical involvement determines impairment 30 years after a clinically isolated syndrome.

Many studies report an overlap of MRI and clinical findings between patients with relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), which in part is reflective of inclusion of subjects with variable disease duration and short periods of follow-up. To overcome these limitations, we examined the differences between RRMS and SPMS and the relationship between MRI measures and clinical outcomes 30 years after first presentation with clinically isolated syndrome suggestive of multiple sclerosis. Sixty-three patients were studied 30 years after their i…

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

BACKGROUND AND OBJECTIVES: Accurate biomarkers that reflect disease activity, severity, and molecular pathophysiology in multiple sclerosis (MS) remain an unmet diagnostic need. We compared the performance of the established biomarkers, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), with emerging candidates in CSF and serum. METHODS: We measured 21 analytes using Olink proximity extension assay technology, NfL and GFAP using Simoa, and soluble triggering receptor expressed on myeloid cells (sTREM2) and neuronal pentraxin 2 (NPTX2) using Fujirebio platforms in pair…

Использование и ограничения нейроглиальных биомаркеров NfL и GFAP в моче в качестве маркеров неинвазивных заболеваний при множественном склерозе.

В качестве важных биомаркеров в MS появляются NFL и GFAP в крови. Анализы на основе мочи могли бы стать более простой, неинвазивной альтернативой; однако ограниченный перенос биомаркеров в мочу может представлять серьезную проблему. Цель этого исследования состояла в том, чтобы оценить обнаруживаемость и диагностический потенциал мочевого и сывороточного систем NfL и GFAP для проведения различия между пациентами, страдающими MS, и здоровыми средствами контроля. МЕТОДЫ: Пробы мочевины и сыворотки у пациентов с релапсирующим MS (RRMS; n = 62) и прогрессивным MS (PMS; n = 17) были проанализирован

A Real-World Experience of Rituximab: A Panacea in Therapy of Multiple Sclerosis in Low- and Middle-Income Settings.

BACKGROUND: Anti-CD20 monoclonal antibodies have received increasing attention in the past few years in the treatment of multiple sclerosis (MS). OBJECTIVES: This study describes the (i) efficacy and safety of rituximab in people living with MS and (ii) assesses clinical and imaging outcomes following rituximab in MS. METHOD: This is a chart review from the MS registry maintained at the institute from a University Hospital in South India. RESULT: Eighty-three (M:F, 26:57) people living with MS received rituximab as immunomodulation between 2007 and 2022 with a median follow-up duration of 1…

Demographic and clinical characterization of multiple sclerosis in Mexico: The REMEMBer study.

BACKGROUND: Multiple sclerosis (MS) is a chronic neurodegenerative disease of the central nervous system with high prevalence in young adults around the world. The vast majority of epidemiological studies and statistics are based on European and American data, so most clinical guidelines and medical consensus are based on this information. There is very limited evidence in Mexico regarding demographic and clinical aspects of MS. Therefore, this study comprehensively described the epidemiological and clinical features of MS in a large cohort of patients from eight tertiary-level centers in Mexi…

Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.

Multiple sclerosis (MS) has conventionally been considered a prototypical autoimmune disorder. While modern immunotherapies effectively control relapsing conditions, they fail to avert progressive neuroinflammation, neurodegeneration, and remyelination failure. This review offers an evidence-based recontextualization. The pathogenesis of multiple sclerosis is multifactorial, resulting from the interaction of genetic predisposition (especially HLA alleles), environmental factors (particularly Epstein-Barr virus infection), B-cell-mediated autoimmunity, and localized CNS inflammation. In this in…

Глиал Цитокин и Метаболические сети в прогрессивном многоразовом склерозе: от патофизиологии до биомаркеров и терапевтических стратегий.

Прогрессивный множественный склероз (ПМС) представляет собой отдельное клиническое и биологическое существо, характеризующееся разрозненной нейроинфламмацией, хронической глиарной активацией и устойчивостью к обычным иммунотерапиям. В отличие от повторного запуска MS, PMS поддерживается постоянными иммунными сетями CNS, где активированные микроглии и астроциты оркестрируют твердую цитокинскую сигнализацию - особенно с участием TNF-α, IL-1β и IL-6 через самовычислительные петли обратной связи. В этом повествовании мы изучаем, как эти цитокины взаимодействуют с окислительным стрессом, накопление

Совпадение в аннотации оригинала
Progressive multiple sclerosis (PMS) represents a distinct clinical and biological entity characterized by compartmentalized neuroinflammation, chronic glial activation, and resistance to conventional immunotherapies. Unlike relapsing MS, PMS is sustained by resident CNS immune networks, where activated microglia and astrocytes orchestrate persistent cytokin…

Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.

PURPOSE OF REVIEW: The review discusses future directions in research on multiple sclerosis and neuromyelitis optica, as long-held beliefs about these diseases are undermined with data from recent clinical trials. RECENT FINDINGS: Results of clinical trials for registration (phase 3) were reported in the last year. Anti-inflammatory approaches, such as daclizumab high-yield process targeting IL-2 receptor, and ocrelizumab targeting CD20 B cells, confirmed a beneficial role of immune suppression in relapsing-remitting disease. And now for the first time achieving the primary end point in prima…

Кислотный профиль эритроцитов по множеству склерозов связан с курсами болезней, липидной пероксидацией и диетическим влиянием.

Предыстория/цели: Диетический образ жизни, в частности потребление жирных кислот (FA), может быть полезным для смягчения основных патогенных процессов при множественном склерозе (MS); однако данные по-прежнему являются недостаточными, особенно в том, что касается передачи болезни. Таким образом, цели этого исследования заключались в изучении эритроцитного профиля АУ у пациентов с релапсирующими (RR)MS и прогрессивными (P)MS, а также в изучении вопроса о том, является ли пищевая добавка пищевой добавкой n-3 PUFA может повлиять на профиль FA, в зависимости от хода болезни. Методы: профиль FA был

Совпадение в аннотации оригинала
Background/Objectives: Dietary lifestyle, particularly the intake of fatty acids (FAs), may be useful in alleviating the key pathogenic processes in multiple sclerosis (MS); however, the data are still scarce, particularly with regard to the course of disease. Therefore, the objectives of this study were to investigate the erythrocyte profile of FAs in patie…

Inferring Multiple Sclerosis Stages from the Blood Transcriptome via Machine Learning.

Peripheral blood mononuclear cells (PBMCs) bear specific dysregulations in genes and pathways at distinct stages of multiple sclerosis (MS) that may help with classifying MS and non-MS subjects, specifying the early stage of disease, or discriminating among MS courses. Here we describe an unbiased machine learning workflow to build MS stage-specific classifiers based on PBMC transcriptomics profiles from more than 300 individuals, including healthy subjects and patients with clinically isolated syndromes, relapsing-remitting MS, primary or secondary progressive MS, or other neurological disord…

Optical coherence tomography (OCT) measurements and disability in multiple sclerosis (MS): A systematic review and meta-analysis.

BACKGROUND: Studies have demonstrated that people with multiple sclerosis (pwMS) experience visual impairments and neurodegenerative retinal processes. The disability progression in pwMS may be associated with retinal changes assessed with optical coherence tomography (OCT). This meta-analysis aims at synthesizing the correlations between OCT measurements of disability in pwMS. METHODS: We systematically searched four databases (PubMed/MEDLINE, Embase, Scopus, and Web of Science) from inception to November 2022, then conducted a meta-analysis using a random effects model to determine the pool…